Health and Healthcare
5864 Articles
Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that…
Dendreon Corporation (NASDAQ: DNDN) is living up to something we showed late in December. It was one of the Top…
For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at…
The biotech sector has seen its share of ups and downs in 2011 and prior years. It is almost always…
Over the last week we have been reviewing some of the “Small Cap Stocking Stuffers” that features the top small…
Many research firms have been coming up with their best ideas lists for 2012. Today brought a list of top…
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is raising cash to help support the commercialization of ponatinib in patients with resistant or…
Some rumors surrounding the world of mergers and acquisitions actually do manage to come true. The newest deal to hit the…
Human Genome Sciences Inc. (NASDAQ: HGSI) is not getting much of a boost despite being called as stock which could…
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks…
AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales…
Pfizer Inc. (NYSE: PFE) has a big day ahead of it. While it has been known for years, it is…
Sequenom, Inc. (NASDAQ: SQNM) has just filed to raise up to $150 million in a mixed securities shelf offering. The…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1…
Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the…
Our top personal finance-related articles today. Your wallet will thank you later.